The WOMAN (World Maternal Antifibrinolytic) Trial Dataset

The WOMAN trial was a large, pragmatic, randomised, double blind, placebo controlled trial to quantify the effects of the early administration of tranexamic acid on death, hysterectomy and other relevant outcomes. This dataset includes the data for 20,060 adult women, who had clinically diagnosed postpartum haemorrhage and who fulfilled the eligibility criteria, who were randomised to receive either TXA or placebo. Relevant data on an entry form was collected before randomisation to assess eligibility and then the woman was randomised. Outcome data was completed at death, discharge from the randomising hospital or 6 weeks (42 days) after randomisation, whichever occurred first. Each row in the dataset represents the full entry and outcome data collected for one woman. Additional information was collected on the sequence of events leading to death to confirm the cause of death. Data may be accessed by visiting https://freebird.lshtm.ac.uk.

Additional Information

The trial was a global collaboration, conducted in 193 hospitals across 21 countries.

Keywords

Postpartum haemorrhage, antifibrinolytic, Tranexamic acid, Maternal health